ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$6.61
+3.53%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.55
From 52W high−22.57%
Volume823008.00
Market cap$680.99M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.55
From 52W high
−22.57%
Volume
823008.00
Market cap
$680.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.5x
P/E (TTM)
—
RSI (14)
39.2
MomentumView details →
1D Return
+3.53%
YTD Return
+34.10%
SummaryUpdated Jun 1, 2026
Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company founded in 1995 and based in Vancouver, Canada. The company focuses on developing cytisinicline, a plant-based alkaloid derived from the golden rain tree, as a smoking cessation and nicotine addiction treatment. After decades of development, Achieve is preparing to submit its New Drug Application (NDA) to the FDA in mid-2025, positioning itself to potentially launch the first new FDA-approved nicotine dependence treatment in nearly 20 years.
Similar companies
Latest newsMore news →
ACHIEVE LIFE SCIENCES, INC. announced inducement equity awards for four new employees, comprising options for 46,500 shares and restricted stock units covering 44,500 shares, and awards for newly appointed CFO Benjamin Halladay comprising an option for up to 200,000 shares and 200,000 restricted stock units.13d agoAchieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer, effective October 5, 2026.18d agoAchieve Life Sciences granted new hire inducement stock options for 315,000 shares and RSUs for 283,000 shares to seven new employees under its 2024 Equity Inducement Plan.46d ago